|
Synonyms: ABR-217620 | ABR217620 | Anyara (proposed trade name) | TTS CD3 | TTS-CD3
Compound class:
Antibody
Comment: Naptumomab estafenatox (ABR-217620) is an immuno-oncology clinical candidate biologic drug that is being developed by Active Biotech and NeoTX Therapeutics. It is a fusion protein containing a 5T4 (tumor-associated oncofetal trophoblast glycoprotein antigen) Fab moiety fused via the C terminus of the heavy chain to an engineered hybrid of Staphylococcus entertoxins A and E (SEA/E-120) superantigens [1]. Staphylococcal superantigens are secreted by the pathogen and stimulate a massive MHC class II-T cell receptor-mediated polyclonal T cell activation, which results in the release of large amounts of cytotoxic and proinflammatory cytokines and potent T-cell-mediated killing of tumour cells. Naptumomab estafenatox targets the destructive power of SEA/E-120 to 5T4-expressing tumour cells. The SEA/E-120 moiety is engineered to reduce MHC class II binding affinity so as to reduce killing of bystander MHC class II positive cells.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Eisen T, Hedlund G, Forsberg G, Hawkins R. (2014)
Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep, 16 (2): 370. [PMID:24445502] |
|
2. Elkord E, Burt DJ, Sundstedt A, Nordle Ö, Hedlund G, Hawkins RE. (2015)
Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α. Oncotarget, 6 (6): 4428-39. [PMID:25669986] |
|
3. Forsberg G, Skartved NJ, Wallén-Ohman M, Nyhlén HC, Behm K, Hedlund G, Nederman T. (2010)
Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity. J Immunother, 33 (5): 492-9. [PMID:20463598] |
|
4. Hawkins RE, Gore M, Shparyk Y, Bondar V, Gladkov O, Ganev T, Harza M, Polenkov S, Bondarenko I, Karlov P et al.. (2016)
A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis. Clin Cancer Res, 22 (13): 3172-81. [PMID:26851187] |
